Biosimilars & More: Decoding Where Pharma R&D Dollars are Going Today

From biosimilars to gene therapy, the pharma pipeline proves out across every stage of innovation.

Biocon advances its pertuzumab biosimilar through European regulators. Akums secures marketing approval for a Helicobacter pylori combikit.

Beacon Therapeutics reports positive late-stage results for a gene therapy that targets inherited vision loss.

These moves reveal where money actually flows and why the industry balances near-term returns with frontier bets.

Investors who track capital allocation today see companies channel R&D dollars into three distinct plays: biosimilars that expand access while protecting margins, combination therapies that drive volume in high-prevalence conditions, and gene therapies that pursue transformative, high-reward outcomes. Three fresh developments make the strategy concrete.

Biosimilars: The Margin and Access Play

Biocon pushes its pertuzumab biosimilar, Pebrilzo, as a direct answer to the commercial reality of HER2-positive breast cancer treatment. The Committee for Medicinal Products for Human Use of the European Medicines Agency recommends marketing authorization for the 420 mg concentrate solution for infusion. The product covers multiple disease stages. The European Commission now reviews the application and prepares its final decision.

Key highlights include:

• Orthogonal and functional analytical characterization plus comparative clinical pharmacokinetic data confirm high similarity to the reference biologic.
• No clinically meaningful differences appear in quality, safety, or efficacy.
• Pebrilzo becomes the first monoclonal antibody biosimilar to receive a positive CHMP opinion under the EMA’s tailored clinical development approach.

Biocon CEO and MD Shreehas Tambe calls the milestone important for biosimilar science and greater regulatory confidence in advanced analytical and clinical pharmacology evidence.

Roche’s Perjeta generated over USD 3.6 billion in sales in 2025. Biocon already locked a 10-year supply contract in Brazil under the Productive Development Partnership program.

Several Indian players like Zydus Lifesciences, Dr Reddy’s, Alkem Laboratories, and Intas Pharma, already market biosimilar alternatives. Capital directed here targets established markets, lower-cost production, and broader patient access while defending margins against innovator pricing.

Also Read: How Can India Pharma Bridge the Gap Between Innovation and Access

Combination Therapies: The Volume Play

Akums Drugs and Pharmaceuticals targets volume through practical, patient-centered formulations. The contract development and manufacturing organization secures marketing approval for a combikit of clarithromycin, vonoprazan, and amoxicillin to treat Helicobacter pylori infection in adults.

Major features of the product stand out:

• Vonoprazan, a potassium-competitive acid blocker, delivers sustained suppression of gastric acid secretion.
• Clarithromycin and amoxicillin provide complementary antibacterial action.
• The regimen requires twice-daily dosing over 14 days.

Sanjeev Jain, MD of Akums, stresses that formulation development addresses evolving healthcare requirements while keeping the practical experience of patients central. This approach channels R&D into combination products that improve adherence and treatment success rates in widespread infections.

Volume potential drives the investment: large patient populations and repeatable therapy cycles create steady revenue streams with relatively contained development risk compared with novel molecules.

Gene Therapy: The High-Risk, High-Reward Frontier

Beacon Therapeutics advances the frontier with laru-zova, an experimental gene therapy for X-linked retinitis pigmentosa. The condition predominantly affects boys and young men.

It begins with night blindness and progresses to narrowing of the peripheral field of vision. No approved treatments currently exist. The disease affects about 4 in 100,000 males across the U.S. and Europe, according to National Institutes of Health data.

Trial results deliver clear proof points:

• The 12-month late-stage study evaluates 85 male subjects aged 12 to 48.
• The therapy meets its primary endpoint: a significant proportion of treated participants improve their ability to read at least 15 additional letters in low-light conditions.
• No participants in the untreated control group achieve this improvement.

CEO Lance Baldo notes that the company now stands as the only one with a study that reads out positively on its primary endpoint within a pivotal phase-three trial, giving it a chronological advantage.

Beacon prepares discussions with global regulatory authorities on a marketing application submission based on these results. Capital allocated here accepts higher risk in exchange for the potential of first-mover status in an area with no existing options and clear unmet need.

Capital Allocation Across the Pipeline

These three stories illustrate a coherent allocation strategy. Biosimilars convert proven molecules into accessible, margin-supporting products. Combination therapies scale volume in common conditions through practical formulation. Whereas gene therapies place high-stakes bets on transformative science.

Together they show investors that R&D dollars move simultaneously across near-term commercial opportunities and long-horizon innovation. The pipeline continues to deliver results at every stage, confirming that diversified capital deployment remains the industry’s operating model today.